Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing life-transforming therapeutics for individuals living with genetically driven neuromuscular diseases. Headquartered in Waltham, Massachusetts, the company's mission is to deliver functional improvement for patients through targeted therapies enabled by its proprietary FORCE™ platform.

The company leverages its FORCE™ platform to develop targeted therapeutics designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne's pipeline includes clinical programs for Myotonic Dystrophy Type 1 (DM1) with product candidate DYNE-101 (z-basivarsen) and Duchenne Muscular Dystrophy (DMD) with DYNE-251 (z-rostudirsen). Additionally, it has preclinical programs targeting Facioscapulohumeral Muscular Dystrophy (FSHD) with DYNE-302 and Pompe disease.

John Cox serves as the President and Chief Executive Officer, having been appointed in March 2024. Recent notable developments include the completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for DM1, with topline data anticipated in the first quarter of 2027. Dyne Therapeutics has also submitted a Biologics License Application (BLA) to the U.S. FDA for z-rostudirsen in Exon 51 Duchenne Muscular Dystrophy, seeking accelerated approval. Furthermore, the company recently expanded its debt facility with Hercules Capital, Inc. to up to $400 million, enhancing its financial flexibility.